Suppr超能文献

基于血液源性 microRNA 特征预测术后肝功能障碍。

Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures.

机构信息

Department of Surgery, Medical University of Vienna, General Hospital, Vienna, Austria.

Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Hepatology. 2019 Jun;69(6):2636-2651. doi: 10.1002/hep.30572. Epub 2019 Apr 10.

Abstract

There is an urgent need for an easily assessable preoperative test to predict postoperative liver function recovery and thereby determine the optimal time point of liver resection, specifically as current markers are often expensive, time consuming, and invasive. Emerging evidence suggests that microRNA (miRNA) signatures represent potent diagnostic, prognostic, and treatment-response biomarkers for several diseases. Using next-generation sequencing as an unbiased systematic approach, 554 miRNAs were detected in preoperative plasma of 21 patients suffering from postoperative liver dysfunction (LD) after liver resection and 27 matched controls. Subsequently, we identified a miRNA signature-consisting of miRNAs 151a-5p, 192-5p, and 122-5p-that highly correlated with patients developing postoperative LD after liver resection. The predictive potential for postoperative LD was subsequently confirmed using real-time PCR in an independent validation cohort of 98 patients. Ultimately, a regression model of the two miRNA ratios 151a-5p to 192-5p and 122-5p to 151a-5p was found to reliably predict postoperative LD, severe morbidity, prolonged intensive care unit and hospital stays, and even mortality before an operation with a remarkable accuracy, thereby outperforming established markers of postoperative LD. Ultimately, we documented that miRNA ratios closely followed liver function recovery after partial hepatectomy. Conclusion: Our data demonstrate the clinical utility of an miRNA-based biomarker to support the selection of patients undergoing partial hepatectomy. The dynamical changes during liver function recovery indicate a possible role in individualized patient treatment. Thereby, our data might help to tailor surgical strategies to the specific risk profile of patients.

摘要

目前迫切需要一种易于评估的术前测试,以预测术后肝功能的恢复情况,从而确定肝切除术的最佳时间点,特别是因为目前的标志物通常既昂贵又耗时,而且具有侵入性。新出现的证据表明,miRNA(miRNA)特征代表几种疾病的有力诊断、预后和治疗反应生物标志物。使用下一代测序作为一种无偏的系统方法,在 21 例术后肝功能障碍(LD)患者和 27 例匹配对照患者的术前血浆中检测到 554 个 miRNA。随后,我们确定了一个 miRNA 特征,由 miRNA 151a-5p、192-5p 和 122-5p 组成,与术后发生 LD 的患者高度相关。随后,在 98 例独立验证队列中使用实时 PCR 进一步证实了该 miRNA 对术后 LD 的预测潜力。最终,发现两个 miRNA 比值 151a-5p 与 192-5p 和 122-5p 与 151a-5p 的回归模型能够可靠地预测术后 LD、严重发病率、延长重症监护病房和住院时间,甚至在手术前预测死亡率,具有显著的准确性,从而优于术后 LD 的既定标志物。最终,我们记录到 miRNA 比值与部分肝切除术后肝功能恢复密切相关。结论:我们的数据证明了基于 miRNA 的生物标志物在支持部分肝切除术患者选择方面的临床应用。在肝功能恢复过程中的动态变化表明其在个体化患者治疗中可能具有作用。因此,我们的数据可能有助于根据患者的特定风险概况调整手术策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验